Immunitybio Inc.
03/31/2025 | Press release | Archived content
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Page Not Found
We are sorry, the page you requested cannot be found. Please check the URL or visit our Homepage.